Product news from the 10/03/06 News Brief

Share this article:
The FDA granted expanded indication to GlaxoSmithKline’s anti-seizure medicine Lamictal (lamotrigine) for treatment of Primary Generalized Tonic-Clonic (PGTC) seizures, also known as "grand mal" seizures, in children aged 2 and older and adults. Axcan Pharma said the FDA has issued an approval letter for the company's New Drug Application for Pylera (formerly Helizide). Pylera is a patented 3-in-1 capsule triple therapy, for the eradication of Helicobacter pylori, a bacterium recognized as being the main cause of gastric and duodenal ulcers. Gilead Sciences has agreed to acquire Myogen in a deal worth approximately $2.5 billion. The deal means that Gilead will acquire Myogen's main drug candidate, Ambrisentan, a pulmonary arterial hypertension treatment in late-stage clinical trials.
Share this article:
You must be a registered member of MMM to post a comment.
close

Next Article in Channel

 

Did you miss January's Top 40 Healthcare Transformers issue? Read how these inventors, strategists, entrepreneurs and wonks are challenging, disrupting and otherwise transforming the healthcare business. And join us April 30 to honor them at the Transforming Healthcare Dinner. Click here.